Database : MEDLINE
Search on : Systemic and Vasculitis [Words]
References found : 11408 [refine]
Displaying: 1 .. 10   in format [Detailed]

page 1 of 1141 go to page                         

  1 / 11408 MEDLINE  
              next record last record
select
to print
Photocopy
Full text

[PMID]: 29214786
[Au] Autor:Kim KY; Bae YS; Ji W; Shin D; Kim HS; Kim DS
[Ad] Address:Department of Pediatrics, Yonsei University College of Medicine, Severance Children's Hospital, Seoul, Korea.
[Ti] Title:ITPKC and SLC11A1 Gene Polymorphisms and Gene-Gene Interactions in Korean Patients with Kawasaki Disease.
[So] Source:Yonsei Med J;59(1):119-127, 2018 Jan.
[Is] ISSN:1976-2437
[Cp] Country of publication:Korea (South)
[La] Language:eng
[Ab] Abstract:PURPOSE: Kawasaki disease (KD) is an acute systemic vasculitis. Both the etiology of KD and the erythema of Bacille Calmette-Guérin (BCG) injection sites observed in the disease are poorly understood. We investigated the association between KD and single nucleotide polymorphisms (SNPs) in two candidate genes: inositol 1,4,5-triphosphate 3-kinase (ITPKC), a well-studied KD-associated gene, and solute carrier 11a1 (SLC11A1), which is associated with the hypersensitive reaction to the BCG strain in Koreans. MATERIALS AND METHODS: Associations between KD and SNPs in two genes were evaluated. Potential associations between BCG injection site erythema and SNPs in two genes were also evaluated. Gene-gene interactions between ITPKC and SLC11A1 in KD and BCG injection site erythema were also analyzed. RESULTS: Three tagging SNPs in ITPKC and five tagging SNPs in SLC11A1 were genotyped in 299 KD patients and 210 control children. SNP rs28493229 in ITPKC was associated with KD and coronary artery complications. SNP rs77624405 in SLC11A1 was associated with KD. Comparisons of KD patients with and without BCG injection site erythema revealed that SNP rs17235409 in SLC11A1 was associated with erythema; no erythema-associated SNPs in ITPKC were identified. Interactions between ITPKC rs28493229_GG and SLC11A1 rs17235409_GA and between ITPKC rs10420685_GG and SLC11A1 rs17235409_AA were strongly associated with BCG injection site erythema. CONCLUSION: This study identified several important polymorphisms in the ITPKC and SLC11A1 genes in Koreans. The genetic variants identified in this study affected KD and erythema of BCG injection sites independently and through gene-gene interactions. Also, the effects of the polymorphisms were age-dependent.
[Mh] MeSH terms primary: Asian Continental Ancestry Group/genetics
Cation Transport Proteins/genetics
Epistasis, Genetic
Genetic Predisposition to Disease
Mucocutaneous Lymph Node Syndrome/genetics
Phosphotransferases (Alcohol Group Acceptor)/genetics
Polymorphism, Single Nucleotide/genetics
[Mh] MeSH terms secundary: BCG Vaccine/administration & dosage
Case-Control Studies
Child
Child, Preschool
Erythema/complications
Female
Genetic Association Studies
Humans
Infant
Male
Mutation Rate
Republic of Korea
[Pt] Publication type:JOURNAL ARTICLE
[Nm] Name of substance:0 (BCG Vaccine); 0 (Cation Transport Proteins); 0 (natural resistance-associated macrophage protein 1); EC 2.7.1.- (Phosphotransferases (Alcohol Group Acceptor)); EC 2.7.1.127 (Inositol 1,4,5-trisphosphate 3-kinase)
[Em] Entry month:1803
[Cu] Class update date: 180309
[Lr] Last revision date:180309
[Js] Journal subset:IM
[Da] Date of entry for processing:171208
[St] Status:MEDLINE
[do] DOI:10.3349/ymj.2018.59.1.119

  2 / 11408 MEDLINE  
              first record previous record next record last record
select
to print
Photocopy
Full text

[PMID]: 29518872
[Au] Autor:Liu ZW; Qiu W; Peng JM; Wang ZW; Zhao JL; Wu QJ
[Ti] Title:[The 461th case: fever, hematuria, and right lumbar pain].
[So] Source:Zhonghua Nei Ke Za Zhi;57(3):229-232, 2018 Mar 01.
[Is] ISSN:0578-1426
[Cp] Country of publication:China
[La] Language:chi
[Ab] Abstract:A 56-year-old female was admitted to the Department of Rheumatology, Peking Union Medical College Hospital with complaint of recurrent fever and acute lumbar pain. Fever was complicated with malaise, cough and occasional blood-streaked sputum. Lab tests showed elevated white blood cell count, increased serum creatinine, erythrocyte sedimentation rate and C-reactive protein. Other lab findings included severe anemia, hematuria, and proteinuria. Immunological examinations were positive for antinuclear antibodies, antineutrophil cytoplasmic antibodies and antiglomerular basement membrane antibody. Ultrasonography and CT scan detected a huge spontaneous perirenal hematoma at right side. Angiography revealed multiple microaneurysms on bilateral renal arteries and branches. A diagnosis of systemic vasculitis was suggested. Under the combination therapy of corticosteroids and cyclophosphamide, the patient presented sustained remission for one year. This case indicates that prompt and sufficient treatment of primary disease is essential to a promising outcome.
[Pt] Publication type:ENGLISH ABSTRACT; JOURNAL ARTICLE
[Em] Entry month:1803
[Cu] Class update date: 180309
[Lr] Last revision date:180309
[St] Status:In-Process
[do] DOI:10.3760/cma.j.issn.0578-1426.2018.03.017

  3 / 11408 MEDLINE  
              first record previous record next record last record
select
to print
Photocopy
Full text

[PMID]: 29279030
[Au] Autor:Arellano K; Mosley JC; Moore DC
[Ad] Address:1 Department of Pharmacy, Southeast Health, Cape Girardeau, MO, USA.
[Ti] Title:Case Report of Ipilimumab-Induced Diffuse, Nonnecrotizing Granulomatous Lymphadenitis and Granulomatous Vasculitis.
[So] Source:J Pharm Pract;31(2):227-229, 2018 Apr.
[Is] ISSN:1531-1937
[Cp] Country of publication:United States
[La] Language:eng
[Ab] Abstract:Ipilimumab is indicated for the treatment of melanoma in both the metastatic and adjuvant setting. Ipilimumab inhibits cytotoxic T-lymphocyte antigen 4, leading to the augmentation of T-cell activity and an antitumor immune system response. The side effect profile of ipilimumab consists of autoimmune-like events such as dermatitis, colitis, and thyroiditis. These immune-related adverse events can be serious, often resulting in the need for systemic immunosuppression with corticosteroids. We present a case of diffuse, nonnecrotizing granulomatous lymphadenitis and granulomatous vasculitis in a heavily pretreated patient with metastatic melanoma. After completion of 4 cycles of ipilimumab for the treatment of metastatic melanoma, our patient complained of increasing fatigue, drenching night sweats, and chills. Imaging revealed diffuse adenopathy involving several lymph nodes. Biopsy was positive for nonnecrotizing granulomatous lymphadenitis and granulomatous vasculitis. High-dose prednisone was initiated and tapered gradually over 6 weeks, resulting in complete resolution of the granulomatous disease.
[Pt] Publication type:JOURNAL ARTICLE
[Em] Entry month:1712
[Cu] Class update date: 180308
[Lr] Last revision date:180308
[St] Status:In-Process
[do] DOI:10.1177/0897190017699762

  4 / 11408 MEDLINE  
              first record previous record next record last record
select
to print
Photocopy
Full text

[PMID]: 28460084
[Au] Autor:van der Meulen PM; Barendregt AM; Cuadrado E; Magro-Checa C; Steup-Beekman GM; Schonenberg-Meinema D; Van den Berg JM; Li QZ; Baars PA; Wouters D; Voskuyl AE; Ten Berge IRJM; Huizinga TWJ; Kuijpers TW
[Ad] Address:Department of Pediatric Hematology, Immunology and Infectious Diseases, Emma Children's Hospital Academic Medical Center.
[Ti] Title:Protein array autoantibody profiles to determine diagnostic markers for neuropsychiatric systemic lupus erythematosus.
[So] Source:Rheumatology (Oxford);56(8):1407-1416, 2017 Aug 01.
[Is] ISSN:1462-0332
[Cp] Country of publication:England
[La] Language:eng
[Ab] Abstract:Objective: The aim was to investigate the association between autoantibodies (autoAbs) and neuropsychiatric (NP) involvement in patients with SLE and to evaluate whether any autoAb or a combination of these autoAbs could indicate the underlying pathogenic process. Methods: Using a multiplexed protein array for 94 antigens, we compared the serum autoAb profiles of 69 NPSLE patients, 203 SLE patients without NP involvement (non-NPSLE) and 51 healthy controls. Furthermore, we compared the profiles of NPSLE patients with clinical inflammatory (n = 38) and ischaemic (n = 31) NP involvement. Results: In total, 75 IgG and 47 IgM autoAbs were associated with SLE patients in comparison with healthy controls. Comparing NPSLE with non-NPSLE and healthy control sera, 9 IgG (amyloid, cardiolipin, glycoprotein 2, glycoprotein 210, heparin, heparan sulphate, histone H2A, prothrombin protein and vimentin) and 12 IgM (amyloid, cardiolipin, centromere protein A, collagen II, histones H2A and H2B, heparan sulphate, heparin, mitochondrial 2, nuclear Mi-2, nucleoporin 62 and vimentin) autoAbs were present at significantly different levels in NPSLE. The combination of IgG autoAbs against heparan sulphate, histone H2B and vimentin could differentiate NPSLE from non-NPSLE (area under the curve 0.845, 99.97% CI: 0.756, 0.933; P < 0.0001). Compared with non-NPSLE, four IgG and seven IgM autoAbs were significantly associated with inflammatory NPSLE. In ischaemic NPSLE, three IgG and three IgM autoAbs were significantly different from non-NPSLE patients. Conclusion: In our cohort, the presence of high levels of anti-heparan sulphate and anti-histone H2B combined with low levels of anti-vimentin IgG autoAbs is highly suggestive of NPSLE. These results need to be validated in external cohorts.
[Mh] MeSH terms primary: Autoantibodies/blood
Lupus Vasculitis, Central Nervous System/diagnosis
[Mh] MeSH terms secundary: Adult
Autoantibodies/immunology
Biomarkers/blood
Case-Control Studies
Female
Heparitin Sulfate/immunology
Histones/immunology
Humans
Immunoglobulin G/immunology
Lupus Vasculitis, Central Nervous System/immunology
Male
Middle Aged
Protein Array Analysis
Vimentin/immunology
[Pt] Publication type:EVALUATION STUDIES; JOURNAL ARTICLE
[Nm] Name of substance:0 (Autoantibodies); 0 (Biomarkers); 0 (Histones); 0 (Immunoglobulin G); 0 (Vimentin); 9050-30-0 (Heparitin Sulfate)
[Em] Entry month:1709
[Cu] Class update date: 180308
[Lr] Last revision date:180308
[Js] Journal subset:AIM; IM
[Da] Date of entry for processing:170502
[St] Status:MEDLINE
[do] DOI:10.1093/rheumatology/kex073

  5 / 11408 MEDLINE  
              first record previous record next record last record
select
to print
Photocopy
Full text

[PMID]: 29246958
[Au] Autor:Kuo HC; Huang YH; Chung FH; Chen PC; Sung TC; Chen YW; Hsieh KS; Chen CS; Syu GD
[Ad] Address:From the ‡Department of Pediatrics and Kawasaki Disease Center, Kaohsiung Chang Gung Memorial Hospital and Chang Gung University College of Medicine, Kaohsiung, Taiwan 83301.
[Ti] Title:Antibody Profiling of Kawasaki Disease Using Proteome Microarrays.
[So] Source:Mol Cell Proteomics;17(3):472-481, 2018 Mar.
[Is] ISSN:1535-9484
[Cp] Country of publication:United States
[La] Language:eng
[Ab] Abstract:Kawasaki disease (KD) is a form of systemic vasculitis that generally occurs in children under 5 years old. Currently, KD is still diagnosed according to its clinical symptoms, including prolonged fever, skin rash, conjunctivitis, neck lymphadenopathy, palm erythema, and oral mucosa changes. Because KD is a type of inflammation without specific marker for diagnosis, we plan to profile the plasma antibodies by using proteome microarray and analyze the differences between KD and healthy subjects. Plasmas were collected from KD patient before intravenous immunoglobulin treatment (KD1), at least 3 weeks after treatment (KD3), nonfever control (NC), and fever control (FC) children. The initial screening, which consisted of 20 KD1, 20 KD3, 20 NC, and 20 FC, were explored using proteome microarrays (∼4200 unique proteins). About ∼70 proteins were shown to have high accuracy, 0.78∼0.92, with regard to separating KD1, KD3, NC, and FC. Those proteins were then purified to fabricate KD focus arrays for training ( = 20 each) and blind-testing ( = 20 each). It only took 125 pl of plasma, less than a drop of blood, in the focus array assays. The AUC scores for blind tests of KD1 NC (17 protein markers), KD1 FC (20 protein markers), KD3 NC (9 protein markers), and KD1 KD3 (6 protein markers) were 0.84, 0.75, 0.99 and 0.98, respectively. This study is the first to profile plasma antibodies in KD and demonstrate that an proteome microarray can screen differences among patients with KD, nonfever controls, and fever controls.
[Pt] Publication type:JOURNAL ARTICLE
[Em] Entry month:1712
[Cu] Class update date: 180307
[Lr] Last revision date:180307
[St] Status:In-Data-Review
[do] DOI:10.1074/mcp.RA117.000198

  6 / 11408 MEDLINE  
              first record previous record next record last record
select
to print
Photocopy
Full text

[PMID]: 28449088
[Au] Autor:Rajapakse S; Weeratunga P; Sivayoganathan S; Fernando SD
[Ad] Address:Tropical Medicine Research Unit, Department of Clinical Medicine, Faculty of Medicine, University of Colombo, 25, Kynsey Road, Colombo 08, Sri Lanka.
[Ti] Title:Clinical manifestations of scrub typhus.
[So] Source:Trans R Soc Trop Med Hyg;111(2):43-54, 2017 02 01.
[Is] ISSN:1878-3503
[Cp] Country of publication:England
[La] Language:eng
[Ab] Abstract:The mite-borne rickettsial zoonosis scrub typhus is widely prevalent in parts of Southeast and Far East Asia, and northern Australia. The disease is an acute febrile illness, associated with rash and often an eschar, which responds dramatically to treatment with antibiotics. In some cases it results in a serious illness leading to multiple organ involvement and death. The disease manifestations are thought to result from a systemic vasculitis, caused by both direct effects of the organisms as well as an exaggerated immune response, although little is understood about its pathogenesis. A wide spectrum of clinical manifestations, affecting nearly every organ system, have been described with scrub typhus. Some of these manifestations are serious and life threatening. In this systematic review, we summarise the typical and atypical manifestations of scrub typhus reported in the literature. Awareness of these unusual manifestations will hopefully guide clinicians towards diagnosing the condition early, and initiating early appropriate antibiotics and other supportive measures.
[Mh] MeSH terms primary: Scrub Typhus
[Mh] MeSH terms secundary: Humans
Orientia tsutsugamushi
Scrub Typhus/complications
Scrub Typhus/diagnosis
Scrub Typhus/immunology
Scrub Typhus/pathology
[Pt] Publication type:JOURNAL ARTICLE; REVIEW
[Em] Entry month:1802
[Cu] Class update date: 180307
[Lr] Last revision date:180307
[Js] Journal subset:IM
[Da] Date of entry for processing:170428
[St] Status:MEDLINE
[do] DOI:10.1093/trstmh/trx017

  7 / 11408 MEDLINE  
              first record previous record next record last record
select
to print
Photocopy
Full text

[PMID]: 29504436
[Au] Autor:Leuchten N; Aringer M
[Ad] Address:Division of Rheumatology, Department of Medicine III, University Medical Center & Faculty of Medicine Carl Gustav Carus at the TU Dresden, Dresden, Germany.
[Ti] Title:Tocilizumab in the treatment of giant cell arteritis.
[So] Source:Immunotherapy;, 2018 Mar 05.
[Is] ISSN:1750-7448
[Cp] Country of publication:England
[La] Language:eng
[Ab] Abstract:Giant cell arteritis is a systemic vasculitis of large vessels, manifesting mainly as temporal arteritis or large vessel vasculitis of the aorta and its branches. Glucocorticoid therapy is essential and so far had to be continued over a period of 1.5-2 years, resulting in relevant morbidity through adverse effects. With the approval of tocilizumab, an effective glucocorticoid sparing option is now available. In two randomized controlled trials, a profound reduction of cumulative glucocorticoid dose, prolonged relapse-free remission and reduced number of adverse events in the treatment groups have been demonstrated. Therefore, tocilizumab constitutes a novel therapeutic option in giant cell arteritis. Its differential role in different subgroups, timing of tocilizumab therapy and optimal treatment duration remain to be determined.
[Pt] Publication type:JOURNAL ARTICLE
[Em] Entry month:1803
[Cu] Class update date: 180305
[Lr] Last revision date:180305
[St] Status:Publisher
[do] DOI:10.2217/imt-2017-0182

  8 / 11408 MEDLINE  
              first record previous record next record last record
select
to print
Photocopy
Full text

[PMID]: 29501300
[Au] Autor:Wang JC; Leader BA; Crane RA; Koch BL; Smith MM; Ishman SL
[Ad] Address:Department of Otolaryngology - Head and Neck Surgery, University of Cincinnati College of Medicine, Cincinnati, OH, USA; Division of Pediatric Otolaryngology - Head and Neck Surgery, Cincinnati Children's Hospital Medical Center, Cincinnati, OH, USA.
[Ti] Title:Granulomatosis with polyangiitis presenting as facial nerve palsy in a teenager.
[So] Source:Int J Pediatr Otorhinolaryngol;107:160-163, 2018 Apr.
[Is] ISSN:1872-8464
[Cp] Country of publication:Ireland
[La] Language:eng
[Ab] Abstract:Granulomatosis with polyangiitis (GPA, previously known as Wegener's granulomatosis) is an autoimmune systemic small-vessel vasculitis, associated with the presence of anti-neurophil cytoplasmic antibodies with a cytoplasmic staining pattern (c-ANCA). It is characterized by necrotizing granulomas, usually affecting the airways and kidneys. GPA should be considered when patients do not improve despite adequate treatment of otologic symptoms, when patients have unspecific symptoms suggesting systemic disease (e.g. fever, malaise), or when other organs are involved (kidney, lungs, etc.). We present an interesting case of a 14-year-old female with eight-weeks of bilateral otalgia, unilateral facial nerve palsy, decreased appetite, and fatigue refractory to steroid, anti-viral, and antibiotic treatment ultimately diagnosed with GPA.
[Pt] Publication type:JOURNAL ARTICLE
[Em] Entry month:1803
[Cu] Class update date: 180304
[Lr] Last revision date:180304
[St] Status:In-Process

  9 / 11408 MEDLINE  
              first record previous record next record last record
select
to print
Photocopy
Full text

[PMID]: 29258731
[Au] Autor:Lin M; Anesi SD; Ma L; Ahmed A; Small K; Foster CS
[Ad] Address:Massachusetts Eye Research and Surgery Institution, Waltham, Massachusetts; Ocular Immunology and Uveitis Foundation, Waltham, Massachusetts; State Key Laboratory of Ophthalmology, Zhongshan Ophthalmic Center, Sun Yat-Sen University, Guangzhou, China.
[Ti] Title:Characteristics and Visual Outcome of Refractory Retinal Vasculitis Associated With Antineutrophil Cytoplasm Antibody-Associated Vasculitides.
[So] Source:Am J Ophthalmol;187:21-33, 2018 Mar.
[Is] ISSN:1879-1891
[Cp] Country of publication:United States
[La] Language:eng
[Ab] Abstract:PURPOSE: To describe the clinical characteristics, therapies, visual outcomes, and prognoses of patients with retinal vasculitis associated with antineutrophil cytoplasmic antibody (ANCA)-associated vasculitides (AAV). DESIGN: Retrospective case series. METHODS: Patients diagnosed with retinal vasculitis associated with AAV and at least 6 months of follow-up were included. Demographic data, systemic and ocular features, best-corrected visual acuity at the initial visit and latest visit, fluorescein angiography (FA) and indocyanine green angiography (ICGA) findings, therapy regimen, and outcome were collected from the Massachusetts Eye Research and Surgery Institution (MERSI) database from 2006 to 2017. RESULTS: Fourteen patients (22 eyes) were identified. Twelve had granulomatosis with polyangiitis (GPA) and 1 each had microscopic polyangiitis (MPA) and eosinophilic granulomatosis with polyangiitis (EGPA). FA showed that AAV affected small-to-medium-size retinal vessels. Seven cases (50%) had both vein/venule and artery/arteriole involvement. Four cases co-presented with choroidal vasculitis. All of them failed various immunomodulatory therapies prior to referral to MERSI. Six patients received rituximab plus prednisone as their final therapy and 5 of them achieved remission. Four patients who failed cyclophosphamide previously were induced into remission by rituximab. Patients were followed for 33.4 ± 25.5 (range 6-84) months. Nine of 14 patients (64.3%) achieved remission at their latest visit. Seventeen of 22 eyes (77.3%) met the criteria for a good (≥20/40) visual outcome. CONCLUSION: The majority of patients enjoyed a good visual outcome and achieved remission after aggressive treatment. Rituximab should be considered as an initial treatment for patients with refractory retinal vasculitis associated with AAV.
[Pt] Publication type:JOURNAL ARTICLE
[Em] Entry month:1712
[Cu] Class update date: 180305
[Lr] Last revision date:180305
[St] Status:In-Data-Review

  10 / 11408 MEDLINE  
              first record previous record
select
to print
Photocopy
Full text

[PMID]: 29500165
[Au] Autor:Moiseev SV; Smitienko I; Bulanov N; Novikov PI
[Ad] Address:Clinic of Nephrology, Internal and Occupational Diseases, Sechenov First Moscow State Medical University, Moscow, Russia.
[Ti] Title:The role of temporal artery biopsy in patients with giant-cell arteritis is debated.
[So] Source:Ann Rheum Dis;, 2018 Mar 02.
[Is] ISSN:1468-2060
[Cp] Country of publication:England
[La] Language:eng
[Pt] Publication type:LETTER
[Em] Entry month:1803
[Cu] Class update date: 180303
[Lr] Last revision date:180303
[St] Status:Publisher


page 1 of 1141 go to page                         
   


Refine the search
  Database : MEDLINE Advanced form   

    Search in field  
1  
2
3
 
           



Search engine: iAH v2.6 powered by WWWISIS

BIREME/PAHO/WHO - Latin American and Caribbean Center on Health Sciences Information